Table 3 HOMA-β and HOMA-IR in Sitagliptin group and Control group
From: Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus
Sitagliptin group (n = 17) | ||||||||
|---|---|---|---|---|---|---|---|---|
Month of Study | 0 | 6 | 12 | 24 | 48 | 72 | 96 | 120 |
HOMA-β | 15.6 (8.81) | 13.1 (8.15) | 19.5 (10.5) | 20.3 (7.41)* | 24.6 (8.60)* | 28.12 (8.91)* | 31.2 (12.2)* | 31.4 (10.41)* |
HOMA-IR | 1.15 (0.74) | 1.14 (0.63) | 1.14 (0.60) | 1.12 (0.59) | 1.15 (0.61) | 1.18 (0.55) | 1.14 (0.61) | 1.15 (0.54) |
Control group (n = 9) | ||||||||
|---|---|---|---|---|---|---|---|---|
Month of Study | 0 | 6 | 12 | 24 | 48 | 72 | 96 | 120 |
HOMA-β | 21.6 (18.7) | 22.0 (16.6) | 19.5 (13.1) | 22.4 (18.7) | 20.9 (21.2) | 21.1 (4.2) | 24.2 (18.5) | 23.2 (18.4) |
HOMA-IR | 1.14 (0.81) | 1.36 (0.67) | 1.27 (0.61) | 1.41 (0.74) | 1.29 (0.76) | 1.21 (0.66) | 1.22 (0.52) | 1.17 (0.50) |